Neuronetics attracts Christopher Thatcher as CEO
This article was originally published in Clinica
Executive Summary
Neuronetics, which specializes in transcranial magnetic stimulation (TMS) for depression, has made Christopher Thatcher president and CEO. Mr Thatcher was most recently divisional vice-president and business unit manager of the Reichert Technology Global Business Unit of Ametek, where he was responsible for revitalizing the brand and expanding the business globally. Prior to this, he was president of Integra Life Sciences’ neurosurgery division and corporate initiatives; vice-president cataract and vitreoretinal surgery at Bausch + Lomb; and held senior sales and marketing roles at Allergan. Neuronetics’ flagship NeuroStar TMS device received US FDA 510(k) clearance in 2008 for drug-resistant depression. Mr Thatcher replaces Bruce Shook, who in July left Neuronetics after 11 years to become president and CEO of Intact Vascular.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.